Stephen Saad’s Aspen to sell European drug rights to Ennogen for $220 million

Aspen Ovestin sale brings $220 million as Stephen Saad's drugmaker sells European rights to Ennogen.

Timilehin Adejumobi November 2, 2026

Business Global News

Kenya’s Mrima Hill mineral race narrows as Chinese bidders withdraw

Kenya's $billions Mrima Hill mineral project draws five international bidders after two Chinese companies withdraw, with three US-linked groups competing.

Oluwatosin Alao November 2, 2026

Hot News Business Companies Latest

Trustco pushes audit to Q4 2026 after 2 years of delayed financial statements

Trustco has pushed completion of its overdue 2024 and 2025 financial audits to Q4 2026, prolonging its JSE trading suspension.

Feyisayo Ajayi November 2, 2026

Fred Arendse, SSC Group CEO & Marula mining COO A. Nethononda

Mining Business Companies

Fred Arendse’s SSC Group strikes $30 million deal for Marula Mining stake

SSC Group strikes a $30 million Marula Mining deal for stakes in two Northern Cape critical minerals projects in South Africa.

Timilehin Adejumobi November 2, 2026

Business Companies Hot News Latest

Sanlam CEO Paul Hanratty steps down from AfroCentric board after 3 years

Sanlam CEO Paul Hanratty has stepped down from AfroCentric’s board after three years, as the healthcare group navigates restructuring challenges.

Feyisayo Ajayi November 2, 2026

Tag: Ennogen Healthcare

Stephen Saad’s Aspen to sell European drug rights to Ennogen for $220 million

Stephen Saad’s Aspen to sell European drug rights to Ennogen for $220 million

Kenya’s Mrima Hill mineral race narrows as Chinese bidders withdraw

Trustco pushes audit to Q4 2026 after 2 years of delayed financial statements

Fred Arendse’s SSC Group strikes $30 million deal for Marula Mining stake

Sanlam CEO Paul Hanratty steps down from AfroCentric board after 3 years

Stephen Saad’s Aspen to sell European drug rights to Ennogen for $220 million

Kenya’s Mrima Hill mineral race narrows as Chinese bidders withdraw

Trustco pushes audit to Q4 2026 after 2 years of delayed financial statements

Categories

About Us

Our Team